Tiziana Life Sciences Ltd (TLSA) Stock Price, Quote & News

Company Profile

Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 20 7495 2379

Website: www.tizianalifesciences.com

Address:

14/15 Conduit Street, London, United Kingdom

GoCubsGo1124 Oct. 24 at 11:52 PM

$TLSA $BULL $LAC $SCHG bullish long term

0 · Reply

HopehelpsU Oct. 24 at 8:13 PM

$TLSA Fackin

1 · Reply

Adriens Oct. 24 at 8:09 PM

$TLSA

0 · Reply

GoCubsGo1124 Oct. 22 at 6:33 PM

$TLSA news? 👀 🐂

1 · Reply

HopehelpsU Oct. 22 at 6:12 PM

$TLSA ODD COMING! CRAZY

0 · Reply

Jddxn Oct. 22 at 6:02 PM

$TLSA 👀

0 · Reply

JthanP Oct. 21 at 10:45 PM

$ spy (Currently $AAPL $MSFT $NVDA $AMZN $TLSA are down AH yet this market doesn't want to fall near all-time highs! What on earth can be keeping it up & why? 🤔 https://m.economictimes.com/news/international/us/u-s-public-debt-hits-record-37-9-trillion-rising-25-billion-daily-as-fiscal-crisis-deepens-is-tariff-policy-enough-as-debt-to-gdp-climbs-124/amp_articleshow/124670871.cms

1 · Reply

BiotechBonesaw Oct. 21 at 1:59 PM

$TLSA buying opportunity long 🚀

1 · Reply

GoCubsGo1124 Oct. 21 at 12:01 PM

$TLSA nice to see a long bullish prediction after any bearish predictions the last week or so. Have a day!

0 · Reply

HopehelpsU Oct. 21 at 11:28 AM

$TLSA So for the doubters, here it is, clear as day, and what's more compelling is that they fortify my DD by actually saying the FDA requested futher information. I did retire at 55, 13 yrs ago, because of embellishments or wishful thinking 🤔.... BUY THE FACKIN DIP! EXTREMELY FACKIN

1 · Reply

Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia

Sep 24, 2025, 8:30 AM EDT - 4 weeks ago

Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress

Sep 15, 2025, 8:00 AM EDT - 5 weeks ago

Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury

Sep 9, 2025, 10:04 AM EDT - 6 weeks ago

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

Sep 5, 2025, 8:30 AM EDT - 7 weeks ago

Tiziana Life Sciences Announces Purchase of Shares by Chairman

Aug 14, 2025, 8:30 AM EDT - 2 months ago

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy

Aug 11, 2025, 9:00 AM EDT - 2 months ago

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

Jul 21, 2025, 7:00 AM EDT - 3 months ago

Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient

Jun 13, 2025, 11:08 PM EDT - 4 months ago

Tiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis Targeting

Jun 13, 2025, 10:30 AM EDT - 4 months ago

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

Jun 13, 2025, 8:30 AM EDT - 4 months ago

Tiziana Life Sciences to Present at the Bio International Convention

May 23, 2025, 7:00 AM EDT - 5 months ago

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease

May 15, 2025, 8:00 AM EDT - 5 months ago

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana's Nasal Foralumab in Study Treating Moderate Alzheimer's Disease

May 9, 2025, 7:00 AM EDT - 6 months ago

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab

May 6, 2025, 7:00 AM EDT - 6 months ago

Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis

Apr 23, 2025, 7:00 AM EDT - 6 months ago

Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial

Apr 2, 2025, 8:00 AM EDT - 7 months ago

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial

Mar 25, 2025, 8:00 AM EDT - 7 months ago

Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial

Mar 17, 2025, 8:00 AM EDT - 7 months ago

Tiziana Life Sciences to Present at the 37th Annual Roth Conference

Mar 14, 2025, 8:30 AM EDT - 8 months ago

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Mar 4, 2025, 8:00 AM EST - 8 months ago

Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial

Feb 27, 2025, 8:00 AM EST - 8 months ago

Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury

Feb 25, 2025, 8:00 AM EST - 8 months ago

Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter

Feb 21, 2025, 8:00 AM EST - 8 months ago

Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC

Feb 18, 2025, 8:00 AM EST - 8 months ago

Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program

Feb 11, 2025, 9:15 AM EST - 9 months ago

Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer's Disease

Jan 23, 2025, 3:00 PM EST - 9 months ago

Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3

Jan 23, 2025, 8:54 AM EST - 9 months ago

Tiziana Life Sciences not to engage in capital raising activities for the immediate future

Jan 22, 2025, 4:05 PM EST - 9 months ago

Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab

Jan 8, 2025, 7:00 AM EST - 10 months ago

Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease

Nov 1, 2024, 1:00 PM EDT - 1 year ago

Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data

Oct 30, 2024, 10:29 PM EDT - 1 year ago

Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million

Aug 19, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Appoints New Chief Executive Officer

Jul 24, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Granted FDA Fast Track Designation

Jun 28, 2024, 11:01 AM EDT - 1 year ago

Tiziana Receives $3.4 Million in Non-Dilutive Funding

Jun 26, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer's Disease with Foralumab

May 30, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research

May 13, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab

Apr 25, 2024, 10:00 AM EDT - 1 year ago

Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab

Apr 23, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program

Apr 22, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program

Apr 19, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®

Apr 18, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology

Apr 11, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology

Mar 5, 2024, 7:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer's Disease

Jan 8, 2024, 7:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients

Jan 5, 2024, 9:30 AM EST - 1 year ago

Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024

Jan 5, 2024, 7:00 AM EST - 1 year ago

Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation

Dec 19, 2023, 7:00 AM EST - 2 years ago

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis

Dec 4, 2023, 7:09 AM EST - 2 years ago

Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar

GoCubsGo1124 Oct. 24 at 11:52 PM

$TLSA $BULL $LAC $SCHG bullish long term

0 · Reply

HopehelpsU Oct. 24 at 8:13 PM

$TLSA Fackin

1 · Reply

Adriens Oct. 24 at 8:09 PM

$TLSA

0 · Reply

GoCubsGo1124 Oct. 22 at 6:33 PM

$TLSA news? 👀 🐂

1 · Reply

HopehelpsU Oct. 22 at 6:12 PM

$TLSA ODD COMING! CRAZY

0 · Reply

Jddxn Oct. 22 at 6:02 PM

$TLSA 👀

0 · Reply

JthanP Oct. 21 at 10:45 PM

1 · Reply

BiotechBonesaw Oct. 21 at 1:59 PM

$TLSA buying opportunity long 🚀

1 · Reply

GoCubsGo1124 Oct. 21 at 12:01 PM

$TLSA nice to see a long bullish prediction after any bearish predictions the last week or so. Have a day!

0 · Reply

HopehelpsU Oct. 21 at 11:28 AM

1 · Reply

HopehelpsU Oct. 21 at 11:20 AM

$TLSA I know when I mention the May 24, 2024 Orphan drug designation application, many here get their panties twisted.... But, listen, as recently as March 2025, in an S-3, the CEO speaks of the ODD FILING as ongoing or pending a decision. I'm still in the camp of a decision that is about to break. I believe they were asked for more information, that could have been in the recent data update, and that would mean a decision is pending and imminent.... Of course this is merely my opinion....but, by mentioning it again, it certainly suggests that they were not denied. EXTREMELY FACKIN

0 · Reply

GoCubsGo1124 Oct. 20 at 1:28 AM

$TLSA have a good week, chat. Our time will come, right?

0 · Reply

Sauce_no_magic Oct. 18 at 9:57 AM

$ETH.X $TLSA $HOOD $SPY this guy loves midnight grilled cheese sandwiches and Jon Cena posters

0 · Reply

DrevanTheStillblade Oct. 16 at 11:34 PM

VRME could be the next $1 to $10 small cap! 🚨 do your own dd $KUKE $TLSA $UGRO $IBG

0 · Reply

GoCubsGo1124 Oct. 16 at 12:53 PM

$TLSA my last post did not go through. I will post again. Looks like we are completing a three-year or so cup and handle. Would be nice if this would hit around that five dollar mark by this time next summer.

1 · Reply

Juststartingout14 Oct. 15 at 11:14 PM

$CRML $EULIF $TLSA this is a great interview. Hearing this makes you realise how important a company like this is for US and Europe. No wonder why they are part of JP Morgan’s 1.5 trillion usd Security and Resiliency Initiativ. China has 95% of the rare earth materials right now…not great.

2 · Reply

CravnBeaver Oct. 15 at 10:08 PM

$EULIF $CRML INTERVIEW FROM YESTERDAY: Our CEO clarifying the PIPE pricing, US investment (cannot be equity, but can be in other forms), and future outlook for CRML. Something EULIF investors sleep on is the ready-to-go lithium mine. The sole mine in Europe that's fully permitted. Tony highlights a great point, those 100 million $TLSA robots will be utilizing lithium batteries. We will be a key player in TSLA's expansion in the EU. It doesn't even have to be TSLA, we will supply whoever wins the robotics race in the EU. Do not sleep on $EULIF at these levels. https://youtu.be/4LsysG1g0xo?si=Qzf-o0Ro3zxOnomx

3 · Reply

GoCubsGo1124 Oct. 15 at 11:49 AM

$TLSA good morning from beautiful Miramar beach. Love the increase in price on Beth low byline yesterday. Can we get this thing above 3$ already? 4$-6$ is also acceptable. Have a great week, chat.

0 · Reply

LetsgoRandy Oct. 14 at 4:28 PM

$SPY Jenny is bullish market because Trump's Big Beautiful Bill is going to return CASH to taxpayers next year. Oh.. where did that CASH come from in the first place? What about paying down the national debt first? What's so beautiful about more government SPENDING? Yes, refunds and tax credits are a form of government spending. In the mean while, EVERYONE pays more TAX due to Trump's tariffs. $DJT $TLSA $UVXY $XRT

1 · Reply

Doozio Oct. 13 at 10:13 PM

$TSLA $TLSA $ESLA 👀 MAMA. YO did say it’s gonna be LGNDary during 🐒🍌🧠⏰♾️ ❤️👑🌈🦄

0 · Reply

User32548888 Oct. 13 at 7:38 PM

$TLSA Call/Put ratio 234/1.

0 · Reply

GoCubsGo1124 Oct. 13 at 4:19 PM

$TLSA our day will come. Not today, but it will come.

1 · Reply

Market Cap	222.01M
Revenue (ttm)	0.00
Net Income (ttm)	-11.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	88,800
Avg Vol	374,762
Day's Range	N/A - N/A
Shares Out	116.85M
Stochastic %K	33%
Beta	-0.37
Analysts	Strong Buy
Price Target	$3.00